投资亮点首次覆盖波士顿科学(BOSTON SCIENTIFIC)(BSX)给予跑赢行业评级,目标价116.00 美元,对应2025 年核心市盈率40 倍,较现价有28%上行空间。公司是正处PFA 大单品放量期的医疗器械巨头。理由如下:波士顿科学为医疗器械领先企业之一。公司成立于1979 年,是全球医疗器械、特别是微创介入领先企业之一。根据我们的统计,按2023 年收入口径:公司位居全球医疗器械第...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.